Brain Health Statistics in US 2026 | Prevention & Treatment

What Is Brain Health and Why It Is a National Priority in 2026

Brain health encompasses the full spectrum of conditions, disorders, and functions that affect how the brain and nervous system develop, operate, age, and deteriorate across a human lifetime. It covers everything from the most common cognitive experiences — headaches, sleep disorders, anxiety, depression — to the most complex and devastating neurodegenerative diseases like Alzheimer’s, Parkinson’s, and ALS, as well as acute events like stroke and traumatic brain injury (TBI), and lifelong conditions like epilepsy, autism, and multiple sclerosis. In the United States, brain health is no longer a niche clinical concern — it is a defining public health challenge of the 21st century. A landmark study published in JAMA Neurology in November 2025 by the American Academy of Neurology and the Institute for Health Metrics and Evaluation delivered one of the most striking findings in modern medicine: more than 54% of the US population — over 180 million Americans out of 332.7 million — is affected by a neurological disease or disorder, making disorders of the nervous system the top cause of disability in the United States. The US, remarkably, has the highest prevalence of diseases affecting the nervous system of any country in the world, higher than any high-income, middle-income, or low-income nation globally.

The human and economic costs of this reality are staggering. 16.6 million disability-adjusted life-years (DALYs) are lost annually to nervous system disorders in the US — more than from any other disease category. Alzheimer’s disease and related dementias alone will cost the nation $384 billion in healthcare and long-term care costs in 2025, a figure projected to rise to nearly $1 trillion by 2050. The $193.2 billion that serious mental illness costs in lost earnings each year adds another dimension to the economic weight. Stroke costs $56.2 billion annually in healthcare services and lost productivity. Against this backdrop, brain health has become a national priority of the first order — driving legislative action from the 21st Century Cures Act’s authorization of the CDC’s National Neurological Conditions Surveillance System to billions of dollars in NIH and private research investment. Understanding the statistics that underpin this crisis is the essential starting point for anyone — patient, caregiver, clinician, policymaker, or researcher — who wants to grasp the true scale of what the US is facing with the health of its most vital and complex organ.

Interesting Key Facts About Brain Health in the US 2026

Source: American Academy of Neurology (AAN) press release, November 24, 2025; JAMA Neurology study by Ney et al. (published November 24, 2025, open access PMC); Yale News Q&A (December 9, 2025); Alzheimer’s Association 2025 Alzheimer’s Disease Facts and Figures; CDC Stroke Facts (October 2024); CDC Facts About TBI (August 4, 2025); Parkinson’s Foundation statistics; NAMI Mental Health by the Numbers (updated 2025); BrightFocus Foundation facts and figures; Nature Medicine 2025 (dementia risk); Neurology journal cognitive disability paper, September 2025

These headline numbers demand a moment of genuine pause. The finding that 54% of Americans have a disorder affecting the nervous system is not the result of overly broad definitions or statistical sleight of hand — it reflects a rigorous, systematic analysis using the Global Burden of Disease 2021 study data, examining 36 unique conditions across the US population of 332.7 million people. The conditions counted range from the most prevalent (tension-type headache affecting 122 million, migraine affecting 58 million) to the most severe (stroke, Alzheimer’s, ALS) — and the sum represents not a philosophical claim about human imperfection but a clinical and epidemiological reality that should reshape how the US allocates healthcare resources. The finding that the US has the highest global prevalence of nervous system disorders of any country — higher than any high-income peer nation — is particularly uncomfortable, and the lead researcher on the JAMA Neurology study has acknowledged that better recognition and reporting explains part of the difference, but structural factors in American healthcare, diet, obesity rates, and systemic health inequities also contribute.

The trajectory behind these numbers is equally alarming. Alzheimer’s surpassing 7 million Americans for the first time in 2025 — up from 6.9 million in 2024 — reflects the aging of the Baby Boomer generation and signals that the numbers will not stabilize on their own. The 42% lifetime dementia risk after age 55 published in Nature Medicine in early 2025 — more than double what prior estimates suggested — means that dementia is not a rare endpoint for extreme old age but a statistically likely experience for a large share of any given generation of Americans. At the other end of the age spectrum, the cognitive disability rate among 18–39 year-olds rising from 10% to 17.8% between 2013 and 2024 points to what researchers are describing as a generational shift in cognitive vulnerability among young adults — a trend that intersects with rising rates of depression, ADHD, PTSD, and other conditions that share cognitive burden with what has historically been considered the domain of aging.

Alzheimer’s Disease and Dementia Statistics in the US 2026

Source: Alzheimer’s Association 2025 Alzheimer’s Disease Facts and Figures (published May 2025; also in Alzheimer’s & Dementia, Wiley/PMC); BrightFocus Foundation Facts and Figures; Nature Medicine March 2025 (Fang et al. dementia lifetime risk); Alzheimer’s Association press release May 6, 2025; North American Community Hub analysis of NIH figures

Alzheimer’s disease represents the most financially and emotionally catastrophic of all brain health conditions in the United States, and the 2025 milestone of 7.2 million Americans living with Alzheimer’s — the first time the number has crossed 7 million — is a population-level alarm bell that the healthcare system is not yet equipped to answer. The trajectory alone is unsustainable: with 900,000+ new cases per year and the current cohort of oldest Baby Boomers (born 1946) turning 80 in 2026, the demographic machinery producing Alzheimer’s cases is not slowing down. The 42% lifetime dementia risk after age 55 published in Nature Medicine in March 2025 rewrites how Americans should be thinking about this disease — it is not a condition that affects someone else’s grandmother, but a statistically near-even-odds proposition for anyone who lives into their 70s and 80s. What makes this particularly urgent is the gap between scale and preparedness: 55% of primary care physicians caring for people with Alzheimer’s report there are not enough dementia care specialists in their communities, and 65% of adults over 65 reside in areas with potential dementia specialist shortfalls.

The gender dimensions of Alzheimer’s are striking and underappreciated in public discourse. Two-thirds of all Americans with Alzheimer’s are women, and the lifetime risk for women at age 45 (1 in 5) is twice that of men (1 in 10). This disparity is driven partly by women’s longer life expectancy — Alzheimer’s risk increases steeply with age — but researchers are also investigating hormonal, genetic, and systemic health factors that may make women independently more vulnerable. The racial disparities are equally pronounced: Black Americans are twice as likely to develop Alzheimer’s as White Americans, and Hispanic Americans are 1.5 times as likely — differences that researchers attribute to a combination of cardiovascular risk factors, socioeconomic determinants, educational disparities, and structural inequities in access to preventive healthcare. These are not incidental background statistics; they are indicators of where Alzheimer’s burden falls most heavily and where the $413 billion in unpaid caregiving is most unequally distributed across American families.

Stroke, TBI and Other Neurological Conditions — US Statistics 2026

Source: CDC Stroke Facts (October 24, 2024); CDC Facts About TBI (August 4, 2025); CDC TBI Data (October 2024); Neurology Advisor brain injury statistics (April 2026); Parkinson’s Foundation statistics; npj Parkinson’s Disease (2022); Frontiers in Aging Neuroscience (GBD 2021 analysis, January 2025); BMC Public Health (February 2025); Annals of Epidemiology (February 2025 — Waltzman et al. CDC); AAN / IHME JAMA Neurology study (November 24, 2025); Brain Injury Association of America (BIAA); AHA Heart Disease and Stroke Statistics 2024 (Circulation); PMC / Neurology journal (2025); CDC NNCSS progress report (September 2024)

The stroke statistics in the US in 2026 represent one of the more complex public health narratives in the brain health space — because the trends are moving in contradictory directions simultaneously. Overall stroke death rates have declined since 2022, reflecting improvements in acute stroke care, hypertension management, and broader cardiovascular health interventions. But the stroke death rate among adults aged 45 to 64 increased by a combined 19% between 2012 and 2021 before partially recovering — a deeply troubling trend suggesting that strokes are striking working-age adults at rising rates. Among Black Americans, the picture is especially alarming: Black men and women experience stroke death rates 2 to 5 times higher than other racial and ethnic groups in certain regions, particularly the South — a geographic clustering in what epidemiologists call the “Stroke Belt” that reflects decades of structural inequality in access to cardiovascular risk management and preventive care. Every 40 seconds someone has a stroke in the US is not an abstract statistic; it is 2,160 strokes per day, each one potentially reshaping the life of a patient and their family.

The Parkinson’s disease picture reveals a condition whose true burden has been systematically undercounted for decades. The 50% upward revision in annual diagnoses — from approximately 60,000 to nearly 90,000 per year — published in the Parkinson’s Foundation’s 2022 incidence study in npj Parkinson’s Disease was not the result of an increase in actual disease but of better epidemiological methodology applied to better data sources. The previous estimate had been based on extrapolation from a study of 26 PD patients in a rural Mississippi county in 1978. The corrected figure has profound implications for healthcare capacity planning: if there are 50% more new PD patients per year than the system was preparing for, the already-strained specialist workforce and care infrastructure is even less adequate than previously understood. The $82.2 billion in annual US healthcare costs for Parkinson’s — and the fact that approximately 4% of PD patients receive their diagnosis before age 50 — means this is not purely a disease of old age but one that disrupts careers, families, and decades of productive life.

Mental Health and the Brain — Key US Statistics 2026

Source: NAMI Mental Health by the Numbers (updated 2025); NIMH Any Anxiety Disorder statistics; NIMH statistics overview; SAMHSA National Survey on Drug Use and Health; USAHS Mental Health Statistics; The Zebra Mental Health Statistics 2026; Neurology journal (Wong et al., September 2025); WHO global productivity data; APA data on workplace mental health

The mental health statistics in 2026 reveal a system under pressure from every direction at once. With 23.4% of US adults — more than 61 million people — experiencing mental illness in 2024, and only about half receiving treatment, the US faces an enormous unmet care gap that has direct consequences for brain health at the population level. Mental illness is not separate from brain health; it IS brain health. Depression, anxiety, ADHD, PTSD, schizophrenia, and bipolar disorder are all fundamentally disorders of how the brain processes information, regulates emotion, and responds to the world — and their prevalence at the scale documented here has cascading consequences for every other brain health outcome. The $193.2 billion in annual lost earnings from serious mental illness alone — a figure that does not include the costs of treatment, hospitalization, or the broader economic ripple effects — illustrates that this is not a clinical problem confined to hospitals and therapy rooms but a macroeconomic force acting across the entire US workforce.

The rising cognitive disability among young adults aged 18–39 deserves sustained scientific and public attention. The jump from 10% in 2013 to 17.8% in 2024 in self-reported cognitive disability in this age group is the kind of trend that does not appear in isolation — it is connected to rising rates of depression, anxiety, long COVID cognitive effects, increased social isolation, the mental health consequences of the pandemic years, and possibly structural changes in sleep, screen time, and other lifestyle factors that affect brain function. Even when researchers excluded young adults with depression from the analysis, cognitive disability still nearly doubled — from 2.8% to 5.2% — suggesting that whatever is driving this generational shift in cognitive vulnerability extends beyond mental health diagnoses alone. This is a scientific signal that the field of brain health research is only beginning to understand, but its public health implications are significant: a generation experiencing higher rates of cognitive disability in their 20s and 30s will carry that burden into middle age and beyond, potentially reshaping the long-term trajectory of America’s brain health burden.

Economic Cost of Brain Health Disorders in the US 2026

Source: Alzheimer’s Association 2025 Alzheimer’s Disease Facts and Figures; Alzheimer’s Association 2025 Executive Summary; Parkinson’s Foundation statistics; Parkinson’s News Today; CDC Stroke Facts (October 2024); NAMI Mental Health by the Numbers (updated 2025); WHO; JAMA Neurology 2025 (AAN/IHME study); PMC GBD Neurological Disorders US Study (Feigin et al.); NCH Stats Alzheimer’s analysis; North American Community Hub

The economic cost of brain health disorders in the US is, by any measure, among the largest and most consequential healthcare expenditures in the world. Alzheimer’s alone, at $384 billion in formal care costs in 2025 plus $413 billion in unpaid caregiver value, represents a combined societal burden approaching $800 billion per year for a single disease. Projecting that to $1 trillion in formal care costs by 2050 — without accounting for inflation, growing unpaid care burden, or the compound costs of the associated comorbidities — creates a picture of fiscal unsustainability that no government budget or insurance system in its current form is designed to absorb. The 22-times-higher Medicaid cost for individuals with dementia compared to older adults without dementia illustrates how disproportionately brain health conditions draw on public healthcare financing — and why the $3.8 billion in federal Alzheimer’s research investment in 2025 represents not just scientific ambition but fiscal survival strategy.

The 1 million additional healthcare worker shortfall projected for dementia care by 2031 — just five years away — is a workforce crisis that is already materializing. With 55% of primary care physicians reporting insufficient specialist availability in their communities, and with the annual wave of new Alzheimer’s cases now exceeding 900,000 per year, the capacity of the US dementia care system is being tested against a demand curve it was not designed to serve. The ripple effects extend well beyond clinical care: the 57% of working caregivers who have had to go in late, leave early, or take time off because of Alzheimer’s caregiving responsibilities represent a quiet economic drain that does not appear in healthcare spending figures but shows up in workforce productivity, employer costs, and caregiver health outcomes. Dementia caregiving is a leading cause of caregiver depression, physical illness, and financial ruin — and none of those cascading costs are fully captured in the headline $384 billion figure.

Brain Health Risk Factors and Prevention in the US 2026

Source: Lancet Commission on Dementia Prevention 2024 update; PMC hemorrhagic stroke and hypertension study 2025; Yale News Q&A with JAMA Neurology lead author December 2025; DoD Traumatic Brain Injury Center of Excellence March 2025; Alzheimer’s Association 2025 Facts and Figures; Parkinson’s Foundation statistics; Frontiers in Aging Neuroscience GBD 2021 PD analysis; CDC NCHS stroke data; npj Parkinson’s Disease 2022; Neurology September 2025 (Wong et al. cognitive disability paper)

The risk factor landscape for brain health offers one of the most actionable and consequential public health messages available: a substantial proportion of brain disease burden is preventable, or at least delayable, through known interventions. The Lancet Commission’s identification of 14 modifiable risk factors accounting for nearly 45% of dementia cases is a finding that should fundamentally reshape how the US approaches public health investment in mid-life. These are not exotic or expensive interventions — treating hypertension, controlling hearing loss, increasing physical activity, reducing social isolation, addressing depression, and reducing tobacco use are all established interventions that the US healthcare system is capable of delivering if sufficiently prioritized. Yet the data shows that the US is underperforming on precisely these risk factors at scale: nearly 48% of US adults have hypertension, which is simultaneously a major risk for stroke, hemorrhagic brain injury, vascular dementia, and Parkinson’s disease — and hypertension management alone could prevent a measurable fraction of the country’s brain disease burden.

The geographic and environmental clustering of brain health conditions — Parkinson’s disease concentrated in the Rust Belt and agricultural regions with heavy pesticide exposure, stroke death rates highest in the South’s Stroke Belt, cognitive disability disproportionately affecting socioeconomically disadvantaged and geographically isolated populations — reveals that where you live in the United States significantly shapes your brain health risk. These are not random distributions; they reflect decades of accumulated environmental exposure, healthcare access disparities, dietary patterns, and structural inequities. The up to 7.5-fold difference in neurological disorder burden between US states is arguably one of the most underappreciated dimensions of American brain health — suggesting that national averages conceal dramatically different realities for Americans depending on their zip code. Addressing brain health in the US in 2026 requires not just better treatments but better understanding of these geographic, racial, and socioeconomic drivers — and the political will to address them.

Brain Health Research and Treatment — Key US Developments 2026

Source: CDC NNCSS progress report (September 2024); North American Community Hub citing NIH; BrightFocus Foundation; Alzheimer’s Association 2025 press release; NIMH FY 2024 Narrative; Annals of Epidemiology (February 2025); npj Parkinson’s Disease (2022); PMC hemorrhagic stroke study (2025); JAMA Neurology / AAN November 2025; Yale News December 2025

The research and treatment landscape for brain health in the US is in a moment of genuine transition — from decades of failed attempts at disease-modifying treatments to the first wave of actually approved interventions. Leqembi (lecanemab) and Kisunla (donanemab), both anti-amyloid antibodies approved between 2023 and 2024, represent the first drugs ever approved by the FDA to slow the clinical progression of Alzheimer’s disease. They are not cures — they slow decline, not reverse it — and they come with significant side effects, high costs, and narrow eligibility criteria. But their existence marks an inflection point: after decades of clinical trial failures, the fundamental scientific hypothesis that clearing amyloid plaques from the brain can modify the disease course has been clinically validated. The blood-based biomarker test guidelines being prepared by the Alzheimer’s Association in 2025 represent the next critical step — making earlier, cheaper, and more accessible diagnosis possible as a precondition for earlier treatment.

The JAMA Neurology study’s call for action — that the US “should prioritize efforts to combat these conditions with new prevention strategies, therapeutics, and focused rehabilitation” — is delivered with the weight of the most comprehensive US neurological burden analysis ever conducted. The study’s finding that the US has the highest prevalence of nervous system disorders of any country on earth, combined with the fact that these disorders are the top cause of disability and produce 16.6 million DALYs annually, provides an evidence base for a national brain health investment that would rival the major cancer and cardiovascular disease initiatives of past decades. The FDA’s own trajectory of approving 8 novel cell and gene therapies in 2024 — many targeting neurological conditions — and the NIH’s substantial research portfolios across Alzheimer’s, Parkinson’s, TBI, and mental illness suggest that the policy and scientific infrastructure for a serious national brain health initiative is beginning to take shape. The question for 2026 and beyond is whether the political will and healthcare financing reform will follow the science.

Disclaimer: The data reports published on The Global Files are sourced from publicly available materials considered reliable. While efforts are made to ensure accuracy, no guarantees are provided regarding completeness or reliability. The Global Files is not liable for any errors, omissions, or damages resulting from the use of these reports.